Latest News About Pancreatic Cancer

Here are the latest developments on pancreatic cancer, based on recent reputable sources:

• FDA expanded access and new approvals in 2026:

  • The FDA announced expanded access for daraxonrasib, a targeted therapy, for patients with metastatic pancreatic cancer, reflecting a potential extension of survival in a subset of patients [pancreatic cancer news sources, 2026]. This aligns with ongoing efforts to bring novel agents to patients outside of traditional trial settings [PanCAN News, 2026].
  • A separate FDA approval in 2026 authorized a wearable device used in combination with chemotherapy for locally advanced pancreatic cancer, representing a new multimodal approach being evaluated to improve outcomes [PanCAN News, 2026].

• Survival and detection context:

  • Pancreatic cancer mortality remains high with five-year survival around the low teens, underscoring the need for early detection and better treatments; multiple organizations have called for increased investment in research and early detection initiatives in response to stagnant survival metrics [PanCAN News, 2026; Pancreatic Cancer Action Network statements, 2025–2026].
  • AI-assisted early detection research is progressing, with studies showing potential to detect pancreatic cancer earlier than current methods, though such tools are not yet standard-of-care and require further validation [Mayo Clinic AI studies; related news reports, 2026].

• Neuroendocrine and other pancreatic cancer subtypes:

  • FDA approvals in 2024–2025 for targeted therapies specific to pancreatic neuroendocrine tumors (PNETs) indicate continued expansion of treatment options for distinct pancreatic cancer subtypes beyond pancreatic ductal adenocarcinoma (PDAC) [FDA press releases, 2024–2025; PanCAN News, 2025].

• Notable research and funding updates:

  • PanCAN and other foundations reported continued investment in research grants aimed at accelerating early detection and novel treatments, highlighting a sector-wide push despite challenges in federal funding [PanCAN press releases, 2024–2025].

If you’d like, I can:

• Pull the most recent articles and summarize key clinical trial results with dates and patient impact.
• Create a short timeline of major FDA approvals and research milestones in 2024–2026.
• Compile a brief overview tailored to your location (Dallas, TX) with local resources and patient support groups.

Would you prefer a focused summary on clinical trials, regulatory updates, or patient support resources? I can also provide a concise list of sources with direct links.